English
新闻
  • 14 2021-01

    Jumpcode Genomics Secures $21M in Series B Funding

    Jumpcode Genomics – a genome technology company focused on improving the understanding of human disease – today announced it raised $21 million in a Series B round of funding. The round was co-led by Baird Capital and Arboretum Ventures and included existing investor LYZZ Capital. Jumpcode also announced the appointment of Frank Witney to its Board of Directors, further expanding the company’s leadership team. Additionally, the company announced the move of its headquarters into larger office and laboratory space.

  • 04 2020-12

    Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

    SAN DIEGO, December 3, 2020 – Qpex Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, announced today that it has initiated a Phase 1 clinical study of QPX7728, its novel ultra-broad-spectrum beta-lactamase inhibitor.

  • 17 2020-08

    捍宇医疗完成总额为5亿人民币D轮融资

    2020年8月13日,捍宇医疗于当日正式宣布完成总额为5亿人民币D轮融资。本轮融资由弘晖资本,CPE,盈科资本联合领投,朗姿韩亚,朗玛峰,幂方资本,东证资本,泰福资本,合方科创以及春风创投跟投。筹集的资金将用于推动公司领先产品Valve Clamp的上市,以及新产品的持续研发

  • 09 2020-06

    NEURELIS ANNOUNCES RAPID AND BROAD PAYER COVERAGE OF THE COMPANY'S FLAGSHIP PRODUCT, VALTOCO® (DIAZEPAM NASAL SPRAY)

    — More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older
    — Neurelis' patient assistance program supports eligible patients who have no health insurance
    — Co-pay program for VALTOCO helps commercial patients lower their out-of-pocket costs to as low as $20

  • 25 2020-04

    纽脉医疗获得B轮追加投资

    继2020年3月,纽脉医疗获得奥博资本(OrbiMed)数千万美金B轮投资后,近日又获得一家国际著名PE机构及达晨财智近亿元人民币的B轮追加投资。本轮融资资金将用于进一步推进国内首款二尖瓣置换介入瓣膜的临床及注册上市。

  • 15 2020-04

    重磅!嘉逸医药首仿“盐酸西那卡塞片”(嘉格平) 获批上市并通过一致性评价

    2020年4月15日,嘉逸药业首仿药物嘉格平(盐酸西那卡塞片)的药品批件获得国家药品监督管理局公示发布。这一重磅品种正式获得NMPA签发的生产批件,用于治疗慢性肾脏病(CKD)维持性透析患者的继发性甲状旁腺功能亢进症,意味着重磅药物盐酸西那卡塞片成功实现国产化!